Skip to main navigation

About Us
Our Science
Our Portfolio
Investors & Media
Careers
- Join Us
- Current Openings
Contact

News Releases

Year

Mar 30, 2023

Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 and Atezolizumab in Hepatocellular Carcinoma

Mar 01, 2023

Omega Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Feb 23, 2023

Omega Therapeutics Announces $40 Million Registered Direct Offering of Common Stock

Jan 17, 2023

Omega Therapeutics to Present Trial-in-Progress Poster for Phase 1/2 MYCHELANGELO™ I Study at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Site - Nav - Investors & Media

Corporate Profile
News & Events
- News Releases
- Events & Presentations
Stock Information
Corporate Governance
Financials & Filings
- SEC Filings
Investor Resources

Presentation

Omega Therapeutics Corporate Overview cover 2022

Corporate Presentation – March 2023 4.5 MB

Investor & Media Contact

ir@omegatherapeutics.com

Site - Investor Tools

Print Page

Email Alerts

RSS Feeds

Contact IR

Search

Home
About Us
Our Science
Our Portfolio
Investors & Media
Careers
Contact Us

20 Acorn Park Drive
Cambridge, MA 02140

contact@omegatherapeutics.com

© Omega Therapeutics, Inc. 2023 All Rights Reserved.
All other trademarks referenced herein are properties of their respective owners.

Terms of use

Privacy Policy